ACV Growth and Guidance Reaffirmation
Annual Contract Value (ACV) grew 8.4% year-over-year to $234.4M (7.8% on a constant currency basis). Management reaffirmed full-year ACV guidance of $240M–$260M (excluding Linkurious-related ACV) with H2 weighting expected.
Nuix Neo Outperformance
Nuix Neo ACV grew 148% on the prior corresponding period to $46.8M, now representing 20% of total ACV. New Neo sales are typically 2–3x the size of non-Neo sales, and migrations typically deliver 30%–50% ACV uplift.
Neo + Neo Discover Mix Shift
Combined Nuix Neo and Nuix Neo Discover now represent 40% of total ACV, indicating a meaningful product mix shift toward the modern platform.
Revenue and Profitability Expansion
Statutory revenue increased 15.2% to $121.2M (12.9% constant currency). Adjusted management EBITDA rose 42.6% to $19.1M, with margin expansion from 12.7% to 15.8%, demonstrating operating leverage.
Material Cash Generation Improvement
Underlying cash flow improved to $28.4M (vs $7.0M in 1H'25) and free cash flow was $20.4M (vs -$7.4M in 1H'25). Closing net cash balance was $57.8M, up 88.4% year-over-year; free cash flow conversion was 149%.
Stronger Regional Performance — EMEA and North America
EMEA ACV led growth at +18.8%, driven by government sector momentum and Neo adoption. North America ACV increased 10.8% with adoption in foundation and investigation solutions and new wins in service providers and financial services.
Product and AI Positioning
Launched a structured Nuix Neo migration program (3-phased: segmentation, migration factory, execute at scale) and reiterated BYO AI framework and enterprise-grade governance as a differentiator. R&D spend of $28.8M (24% of revenue) continued to fund roadmap and AI investments.